UK biotech Antiverse has raised $9.3 million to accelerate its drug discovery programmes, based on an AI-powered platform for ...
The FDA has started a review of Hansa Biopharma's imlifidase for patients who need a kidney transplant, but for whom finding ...
Italy's AI Law establishes new criminal offenses, creating meaningful risks for US executives and employees. The law ...
Shares in PepGen were down more than 21% after the FDA placed a partial clinical hold on its lead drug PGN-EDODM1, for rare ...
Lilly will make its Zepbound KwikPen (tirzepatide) – which delivers four weekly injections in one device – available through the programme at a cost of $449 across all doses for an individual patient, ...
They found that after three years of follow-up, the group taking GLP-1 agonists like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide were 14% less likely to develop substance use disorders ...
What emerged through such discussions was not optimism nor was it pessimism, but clarity. The consensus was striking in its consistency across sessions. JPM 2026 signalled genuine recovery – but not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results